Fertility and Sterility
Volume 89, Issue 2 , Pages 311-317 , February 2008

Peroxisome proliferator-activated receptor-γ ligand reduced tumor necrosis factor-α-induced interleukin-8 production and growth in endometriotic stromal cells

Received 9 November 2006 ,Revised 14 February 2007 ,Accepted 8 March 2007.

References 

  1. Harada T, Yoshioka H, Yoshida S, Iwabe T, Oonohara Y, Tanikawa M, et al. Increased interleukin-6 levels in peritoneal fluid of infertile patients with active endometriosis. Am J Obstet Gynecol. 1997;176:593–597
  2. Iwabe T, Harada T, Tsudo T, Tanikawa M, Oonohara Y, Terakawa N. Pathogenetic significance of increased levels of interleukin-8 in the peritoneal fluid of patients with endometriosis. Fertil Steril. 1998;69:924–930
  3. Iwabe T, Harada T, Tsudo T, Nagano Y, Yoshida S, Tanikawa M, et al. Tumor necrosis factor-α promotes proliferation of endometriotic stromal cells by inducing interleukin-8 gene and protein expression. J Clin Endocrinol Metab. 2000;85:824–829
  4. Sakamoto Y, Harada T, Horie S, Iba Y, Taniguchi F, Yoshida S, et al. Tumor necrosis factor-α-inducing interleukin-8 (IL-8) expression in endometriotic stromal cells, probably through nuclear factor-κB activation: gonadotropin-releasing hormone agonist treatment reduced IL-8 expression. J Clin Endocrinol Metab. 2003;88:730–735
  5. Henzel M, Kwei L. Efficacy and safety of nafarelin in the treatment of endometriosis. Am J Obstet Gynecol. 1990;162:570–574
  6. Dlugi AM, Miller JD, Knittle J. Lupron depot (leuprolide acetate for depot suspension) in the treatment of endometriosis: a randomized, placebo-controlled, double blind study. Fertil Steril. 1990;54:419–427
  7. Surrey ES, Hornstein MD. Prolonged GnRH agonist and add-back therapy for symptomatic endometriosis: long-term follow-up. Obstet Gynecol. 2002;99:709–719
  8. Crosignani P, Olive D, Bergvist A, Luciano A. Advances in the management of endometriosis: an update for clinicians. Hum Reprod Update. 2006;12:179–189
  9. Hornung D, Waite LL, Ricke EA, Bentzien F, Wallwiener D, Taylor RN. Nuclear peroxisome proliferators-activated receptor α and γ have opposing effects on monocyte chemotaxis in endometriosis. J Clin Endocrinol Metab. 2001;86:3108–3144
  10. Lebovic DI, Kir M, Casey CL. Peroxisome proliferators-activated receptor-gamma induces regression of endometrial explants in a rat model of endometriosis. Fertil Steril. 2004;82(Suppl 3):1008–1013
  11. Dermirturk F, Aytan H, Cahskan AC, Aytan P, Koseoglu DR. Effect of Peroxisome proliferators-activated receptor-gamma agonist Rosiglitazone on the induction of endometriosis in an experimental rat model. J Soc Gynecol Investing. 2006;13:58–62
  12. Staels B, Fruchart JC. Therapeutic roles of peroxisome proliferators-activated receptor agonists. Diabetes. 2005;54:2460–2470
  13. Syrovets T, Gschwend J, Buchele B, Laumonnier Y, Zugmaier W, Felicitas G, et al. Inhibition of IκB kinase activity by acetyl-boswellic acids promotes apoptosis in androgen-independent PC-3 prostate cancer cells in vitro and in vivo. J Biol Chem. 2005;280:6170–6180
  14. Harada T, Iwabe T, Terakawa N. Role of cytokines in endometriosis. Fertil Steril. 2001;76:1–10
  15. Li Q, Verman IM. NF-κB regulation in the immune system. Nat Rev Immunol. 2002;2:725–734
  16. Hornung D, Bentzien F, Wallweiner D, Kiesel L, Taylor RN. Chemokine bioactivity of RANTES in endometriotic and normal endometrial stromal cells and peritoneal fluid. Mol Hum Reprod. 2001;7:163–168
  17. Pritts EA, Zhao D, Ricke E, Waite L, Taylor RN. PPAR-gamma decreases endometrial stromal cell transcription and translation of RANTES in vitro. J Clin Endocrinol Metab. 2002;87:1841–1844
  18. Pritts EA, Zhao D, Sohn SH, Chao VA, Waite LL, Taylor RN. Peroxisome proliferator-activated receptor-γ ligand inhibition of RANTES production by human endometriotic stromal cells is mediated through an upstream element. Fertil Steril. 2003;80:415–420
  19. Kodera Y, Takeyama K, Murayama A, Suzawa M, Masuhiro Y, Kato S. Ligand type-specific interactions of peroxisome proliferator-activated receptor gamma with transcriptional coactivators. J Biol Chem. 2000;275:33201–33204
  20. Chung SW, Kang BY, Kim SH, Pak YK, Cho D, Trinchieri G, et al. Oxidized low density lipoprotein inhibits interleukin-12 production in lipopolysaccharide-activated mouse macrophages via direct interactions between peroxisome proliferator-activated receptor-gamma and nuclear factor-kappa B. J Biol Chem. 2000;275:32681–32687
  21. Lin YZ, Yao SY, Veach RA, Torgerson TR, Hawiger J. Inhibition of nuclear translocation of transcription factor NF-κB by a synthetic peptide containing a cell membrane permeable motif and nuclear localization sequence. J Biol Chem. 1995;270:14255–14258
  22. Daynes RA, Jones DC. Emerging roles of PPARs in inflammation and immunity. Nat Rev Immunol. 2002;2:748–759
  23. Blevisi MG, Hela DJ, Birrel MA. Peroxisome proliferator-activated receptor gamma agonists as therapy for chronic airway inflammation. Eur J Pharmacol. 2006;533:101–109
  24. Su CG, Wen X, Bailey ST, Jiang W, Rangwala SM, Keilbaugh SA, et al. A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response. J Clin Invest. 1999;104:383–389

PII: S0015-0282(07)00618-8

doi: 10.1016/j.fertnstert.2007.03.061

Fertility and Sterility
Volume 89, Issue 2 , Pages 311-317 , February 2008

Article Tools

* Image Usage & Resolution